Results 241 to 250 of about 5,525,673 (387)

High-Power-Density Rechargeable Hybrid Alkali/Acid Zn-Air Battery Performance Through Value-Added Conversion Charging. [PDF]

Adv Sci (Weinh)
Yin X, Sun W, Chen K, Lu Z, Chen J, Cai P, Wen Z.   +6 more
europepmc   +1 more source

Extending the Endurance, Missions and Capabilities of Most UAVs Using Advanced Flexible/Ridged Solar Cells and New High Power Density Batteries Technology

, 2011
Chee Keen. Chin
openalex   +1 more source

Clinical Conditions Associated With a High Antinuclear Antibody Titer in Individuals Without Autoimmune Disease

Arthritis Care &Research, EarlyView.
Objective Antinuclear antibodies (ANAs) are present at high titers in 2% of the general population, but their clinical significance in individuals without an autoimmune (AI) disease is not known. We tested the hypothesis that the presence of a high ANA titer in non‐AI conditions is associated with disease.
Matthew Chung, John P. Shelley, Gul Karakoc, John Still, Xiaodi Ruan, Jonathan Mosley, C. Michael Stein, Vivian K. Kawai   +7 more
wiley   +1 more source

Development of GaN-Based, 6.6 kW, 450 V, Bi-Directional On-Board Charger with Integrated 1 kW, 12 V Auxiliary DC-DC Converter with High Power Density. [PDF]

Micromachines (Basel)
Reali A, Alemanno A, Ronchi F, Rossi C, Florian C.   +4 more
europepmc   +1 more source

Finite Element Modeling of Five Phase Permanent Magnet BLDC Motor for High Power Density Application

, 2013
Kiran George, Shinoy K.S., Sija Gopinathan   +2 more
openalex   +1 more source

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

Arthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti, Inmaculada C. Penadés, Irina Nikishina, Ivan Foeldvari, Alberto J. Spindler, Anna Kozlova, Nadina Rubio‐Pérez, Pierre Quartier, Zbigniew Żuber, Raul Barria, Daniel Clemente, Gabriel V. Cornejo, Katherine Marzan, Nancy Liu, Christine Xu, Stephen DiMartino, Angeliki Giannelou, Fei Cao‐Ghoul, Bolanle Akinlade, Lydie Baret‐Cormel   +19 more
wiley   +1 more source

Balancing Edge Defects and Graphitization in a Pt-Fe/Carbon Electrocatalyst for High-Power-Density and Durable Flow Seawater-Al/Acid Hybrid Fuel Cells and Zn-Air Batteries. [PDF]

Adv Sci (Weinh)
Li H, Zhang M, Wang M, Du M, Wang Z, Zou Y, Pan G, Zhang J.   +7 more
europepmc   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, Accepted Article.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; NCT04179032) used three‐weight‐band ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) network investigators   +14 more
wiley   +1 more source

Synergistic effect of quinary molten salts and ruthenium catalyst for high-power-density lithium-carbon dioxide cell. [PDF]

Nat Commun, 2020
Baek K, Jeon WC, Woo S, Kim JC, Lee JG, An K, Kwak SK, Kang SJ.   +7 more
europepmc   +1 more source